Emcure’s Bold Pricing Move: Expanding Access in India’s Weight-Loss Drug Market

has taken a strategic step by slashing the price of its weight-management drug Poviztra (semaglutide injection) by up to 55%, bringing the starting monthly cost for the 0.25 mg dose down from ₹8,790 to ₹3,999, while the highest 2.4 mg maintenance dose is now priced at ₹8,999 vs ₹15,000 earlier, implying an average price reduction of करीब 47% across all dosage strengths; the drug, available in five strengths (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and administered via a once-weekly pen (₹999 per week for entry dose), will see revised pricing effective April 3, 2026, aimed at improving affordability and widening patient access in a country facing a growing obesity burden (estimated 254 million general obesity and 351 million abdominal obesity cases), while also intensifying competition in India’s fast-growing GLP-1 segment especially after global innovator Novo Nordisk reduced prices of its drugs Ozempic by 36% and Wegovy by 48%, and amid the entry of 17+ generic versions that have already lowered treatment costs by up to 90%, positioning this move as both a market-share play and a public-health-driven pricing strategy. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.